This communication highlights the development of a nicotinamide series of histone deacetylase inhibitors within the benzamide structural class. Extensive exploration around the nicotinamide core led to the discovery of a class I selective HDAC inhibitor that possesses excellent intrinsic and cell-based potency, acceptable ancillary pharmacology, favorable pharmacokinetics, sustained pharmacodynamics in vitro, and achieves in vivo efficacy in an HCT116 xenograft model.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bmcl.2007.08.023 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!